| CPE | cardiac pulmonary edema; chronic pulmonary emphysema; clinical progress exercise; compensation, pens... |
|---|---|
| DCE | desmosterol-to-cholesterol enzyme |
| DME | degenerative myoclonus epilepsy; dimethyl diester; dimethyl ether; diphasic meningoencephalitis; dir... |
| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
| ED | early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff... |
| tests of criminal responsibility | In forensic psychiatry, legal precedents upon which are based decisions concerning insanity in criminals. See: American Law Institute rule, Durham rule, M'Naghten rule, New Hampshire rule. (05 Mar 2000) |
|---|---|
| toxicity tests | Tests that determine the toxicity of a substance. These include tests of clinical drugs, foods, environmental pollutants, etc. (12 Dec 1998) |
| fallopian tube patency tests | Methods for assessing the patency of the fallopian tubes. (12 Dec 1998) |
| flocculation tests | Precipitin tests in which precipitation occurs over a narrow range of antigen-antibody ratio, due chiefly to peculiarities of the antibody (precipitin). (12 Dec 1998) |
| language tests | Tests designed to assess language behaviour and abilities. They include tests of vocabulary, comprehension, grammar and functional use of language, e.g., development sentence scoring, receptive-expressive emergent language scale, parsons language sample, utah test of language development, michigan language inventory and verbal language development scale, illinois test of psycholinguistic abilities, northwestern syntax screening test, peabody picture vocabulary test, ammons full-range picture vocabulary test, and assessment of children's language comprehension. (12 Dec 1998) |
| latex fixation tests | Passive agglutination tests in which antigen is adsorbed onto latex particles which then clump in the presence of antibody specific for the adsorbed antigen. (12 Dec 1998) |
| acetyl-activating enzyme | A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate. Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase. (05 Mar 2000) |
| acyl-activating enzyme | <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine Registry number: EC 6.2.1.3 Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme (26 Jun 1999) |
| adaptive enzyme | Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates. Compare: constitutive enzyme. Synonym: adaptive enzyme. (05 Mar 2000) |
| allosteric enzyme | <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site. (09 Oct 1997) |
| amino acid activating enzyme | <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate. Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases. (05 Mar 2000) |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| angiotensin-converting enzyme secretase | <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline Registry number: EC 3.4.99.- Synonym: ace secretase (26 Jun 1999) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |